November 20, 2019
Boston Business Journal: Keytruda researcher launches cancer-focused Werewolf Therapeutics with $56M
One of the researchers behind Merck's blockbuster cancer drug Keytruda has launched a new startup with the aim of expanding the drug industry's ability to leverage the immune system against cancer. Werewolf Therapeutics has emerged from stealth mode with $56 million from MPM Capital, the Longwood Fund and others.
Boston Business Journal
By Allison DeAngelis